2-氯-4-三氟甲氧基碘苯 | 345226-19-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-氯-4-三氟甲氧基碘苯
• 中文别名: 2-氯-4-三氟甲氧基碘代苯；3-氯-4-碘-1-三氟甲氧基苯
• 英文名称: 2-chloro-1-iodo-4-(trifluoromethoxy)benzene
• 英文别名: 3-chloro-4-iodophenyl trifluoromethyl ether；2-chloro-4-triflouromethoxyiodobenzene
• CAS: 345226-19-9
• 化学式: C₇H₃ClF₃IO
• mdl: MFCD08458089
• 分子量: 322.453
• InChiKey: NFAJTTNPYSKSCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2909309090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

2-氯-4-三氟甲氧基碘苯MSDS英文版

反应信息

• 作为反应物：
  描述：

  2-氯-4-三氟甲氧基碘苯 在 正丁基锂 、 溶剂黄146 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.75h， 生成 (S)-N-(2-chloro-4-trifluoromethoxybenzyl)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-amine
  参考文献：
  名称：

  Structure–Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824).

  摘要：

  The (S)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine named PA-824 (1) has demonstrated antitubercular activity in vitro and in animal models and is currently in clinical trials. We synthesized derivatives at three positions of the 4-(trifluoromethoxy)benzylamino tail, and these were tested for whole-cell activity against both replicating and nonreplicating Mycobacterium tuberculosis (Mtb). In addition, we determined their kinetic parameters as substrates of the deazaflavin-dependent nitroreductase (Ddn) from Mtb that reductively activates these pro-drugs. These studies yielded multiple compounds with 40 nM aerobic whole cell activity and 1.6 mu M anaerobic whole cell activity: 10-fold improvements over both characteristics from the parent molecule. Some of these compounds exhibited enhanced solubility with acceptable stability to microsomal and in vivo metabolism. Analysis of the conformational preferences of these analogues using quantum chemistry suggests a preference for a pseudoequatorial orientation of the linker and lipophilic tail.

  DOI：

  10.1021/jm1010644
• 作为产物：
  描述：

  2-氯-4-(三氟甲氧基)苯胺盐酸盐 在 盐酸 、 sodium nitrite 、 potassium iodide 作用下， 以 水 为溶剂， 反应 19.0h， 以74.2%的产率得到2-氯-4-三氟甲氧基碘苯
  参考文献：
  名称：

  [EN] SUBSTITUTED [1,2,4]TRIAZOLE COMPOUNDS AS FUNGICIDES
  [FR] COMPOSÉS DE [1,2,4]TRIAZOLE SUBSTITUÉS UTILISÉS EN TANT QUE FONGICIDES

  摘要：

  本发明涉及公式I的取代[1,2,4]三唑化合物及其N-氧化物和盐，以及所述化合物的使用方法和用于 bekämpfung 植物病原真菌的方法，以及至少涂覆有一种该化合物的种子。本发明还涉及制备这些化合物的方法和包含至少一种化合物I的组合物。

  公开号：

  WO2021249800A1

文献信息

• [EN] NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY<br/>[FR] NITROIMIDAZOOXAZINES ET LEURS UTILISATIONS EN THÉRAPIE ANTITUBERCULEUSE
  申请人：GLOBAL ALLIANCE FOR TB DRUG DEV

  公开号：WO2011014774A1

  公开（公告）日：2011-02-03

  The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

  本发明涉及新型硝基咪唑噁啉类化合物，其制备方法，以及它们作为治疗结核分枝杆菌和其他微生物感染的药物的用途，可以单独使用或与其他抗感染治疗方法结合使用。
• NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY
  申请人：Denny William Alexander

  公开号：US20120028973A1

  公开（公告）日：2012-02-02

  The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

  本发明涉及新型硝基咪唑噁啉类化合物，其制备方法，以及它们作为治疗结核分枝杆菌和其他微生物感染的药物的用途，可以单独使用或与其他抗感染治疗联合使用。
• Rhodium-Catalyzed Aldehyde Arylation via Formate-Mediated Transfer Hydrogenation: Beyond Metallic Reductants in Grignard/Nozaki–Hiyami–Kishi-Type Addition
  作者：Robert A. Swyka、Wandi Zhang、Jeffery Richardson、J. Craig Ruble、Michael J. Krische

  DOI：10.1021/jacs.8b13652

  日期：2019.2.6

  intermolecular carbonyl arylations via transfer hydrogenative reductive coupling are described. Using rhodium catalysts modified by tBu2PMe, sodium formate-mediated reductive coupling of aryl iodides with aldehydes occurs in a chemoselective fashion in the presence of protic functional groups and lower halides. This work expands the emerging paradigm of transfer hydrogenative coupling as an alternative to pre-formed

  描述了通过转移氢化还原偶联的第一个分子间羰基芳基化。使用 tBu2PMe 改性的铑催化剂，甲酸钠介导的芳基碘化物与醛的还原偶联在质子官能团和低级卤化物存在下以化学选择性方式发生。这项工作扩展了转移氢化偶联的新兴范例，作为 C=X 加成中预形成的碳负离子或金属还原剂的替代品。
• [EN] AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES<br/>[FR] DÉRIVÉS DE CYCLOHEXANE À SUBSTITUTION AMIDO
  申请人：BAYER PHARMA AG

  公开号：WO2016177658A1

  公开（公告）日：2016-11-10

  The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredient.

  本发明涉及一般式(I)的酰胺取代环己烷化合物，其中A、R4、R6、R7、R8、R9、R10和R11如本文所定义，涉及制备所述化合物的方法，涉及用于制备所述化合物的中间化合物，涉及包含所述化合物的药物组合物和药物组合物，以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途，特别是肿瘤，作为唯一药剂或与其他活性成分结合使用。
• Novel imidazopyrimidinyl and imidazopyri dinyl derivatives
  申请人：——

  公开号：US20040229887A1

  公开（公告）日：2004-11-18

  Provided herein are compounds of the formula (I): 1 as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful in the treatment of a variety of disorders characterized by execssive CRF expression. These include, for example: affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia.

  本文提供了公式（I）化合物，以及其立体异构体和药学上可接受的盐。这些化合物由于其对CRF的拮抗作用，在治疗许多由于CRF过度表达引起的疾病方面非常有用。这些疾病包括：情感障碍、焦虑、抑郁、头痛、肠易激综合征、创伤后应激障碍、上核性麻痹、免疫抑制、阿尔茨海默病、亨廷顿病、帕金森病、肌萎缩侧索硬化、胃肠疾病、厌食症或其他进食障碍、药物成瘾、药物或酒精戒断症状、炎症性疾病、心血管或心脏相关疾病、生育问题、人类免疫缺陷病毒感染、出血性应激、肥胖症、头部和脊髓创伤、癫痫、中风、溃疡、肌萎缩侧索硬化和低血糖症。